Sana Biotechnology initiated with a Buy at Jefferies

Jefferies analyst Roger Song initiated coverage of Sana Biotechnology (SANA) with a Buy rating and $7 price target Sana is a clinical stage biotech focused on bringing engineered cells as medicines to market by leveraging its proprietary hypo-immune editing platform, the analyst tells investors in a research note. The firm says the company has three assets in development for three different disease spaces. It models peak adjusted revenues of $2.8B.